Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Avapro (irbesartan) Tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – December 2011

Summary View

 

PRECAUTIONS

Drug Interactions
  • Concomitant use of potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.

 

ADVERSE REACTIONS

Post-Marketing Experience
  • Thrombocytopenia
  • Impaired renal function, including cases of renal failure, has been reported.
  • Cases of increased CPK and rhabdomyolysis have been reported in patients receiving angiotensin II receptor blocker.
-
-